In this manuscript, the authors, Davidi et al have investigated the effect of TTFields in HCC cells and an animal model, alone or in combination with sorafenib.
What is puzzling in this investigation is showing functional data using two human cell lines and in vivo data using rat cells. While I do not know if the authors have the technology to perform TTFileds in mice, where for sure they should have done xenograft models with the two human cell lines, why the rat cell line was not studied in vitro using the same experimental strategies as for human cells. This must be done and included for a better understanding of TTFieldds activity from in vitro to in vivo data. What are the p53 status and the apoptosis signaling pathway function in N1S1 cells? Maybe the cytotoxicity data will reveal a different better frequency.